Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
20 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
134 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
52
52 articles ont été cités au moins 52fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
16 587
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
469
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
140
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Paris-Saclay · Institut Gustave Roussy · Arcagy Gineco
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database
2026ArticleInternational Journal of Gynecological Cancer
Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case–control study
2025ArticleBMC Medicine
Maintenance after first-line treatment for advanced soft tissue sarcoma
2025ArticleCritical Reviews in Oncology/Hematology
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database
2025ArticleGynecologic Oncology
Deep learning can accurately predict the prognosis of gynecologic smooth muscle tumors of uncertain malignant potential: a multicenter pilot study
2025ArticleLaboratory Investigation
Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer.
2025CongrèsAmerican Society of Clinical Oncology (ASCO) Annual meeting 2025
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network
2025ArticleOncologist
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas
2025ArticleInternational Journal of Gynecological Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
INSTITUT GUSTAVE ROUSSY
39 B R CAMILLE DESMOULINS, 94805 VILLEJUIF CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic with bevacizumab and chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), a placebo-controlled double-blinded randomized phase III trial, enrolled patients with recurrent epithelial OC, one to two previous chemotherapy lines, and PFI >6 months. Eligible patients were randomly assigned 2:1 to atezolizumab (1,200 mg once every 3 weeks or equivalent) or placebo for up to 24 months, combined with bevacizumab and six cycles of chemotherapy doublet, stratified by PFI, PD-L1 status, and chemotherapy regimen. Coprimary end points were investigator-assessed progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1–positive populations (alpha .025 for each population). RESULTS Between September 2016 and October 2019, 614 patients were randomly assigned: 410 to atezolizumab and 204 to placebo. Only 38% had PD-L1–positive tumors. After 3 years' median follow-up, the PFS difference between atezolizumab and placebo did not reach statistical significance in the ITT (hazard ratio [HR], 0.83; 95% CI, 0.69 to 0.99; P = .041; median 13.5 v 11.3 months, respectively) or PD-L1–positive (HR, 0.86; 95% CI, 0.63 to 1.16; P = .30; median 15.2 v 13.1 months, respectively) populations. The immature overall survival (OS) HR was 0.81 (95% CI, 0.65 to 1.01; median 35.5 v 30.6 months with atezolizumab v placebo, respectively). Global health-related quality of life did not differ between treatment arms. Grade ≥3 adverse events (AEs) occurred in 88% of atezolizumab-treated and 87% of placebo-treated patients; grade ≥3 AEs typical of immunotherapy were more common with atezolizumab (13% v 8%, respectively). CONCLUSION ATALANTE/ENGOT-ov29 did not meet its coprimary PFS objectives in the ITT or PD-L1–positive populations. OS follow-up continues. Further research on biopsy samples is warranted to decipher the immunologic landscape of late-relapsing OC.
The New England journal of medicine · 2024
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
PURPOSE To compare standard versus extended duration of bevacizumab treatment in combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV ovarian cancer. METHODS In this multicenter, open-label, randomized phase III trial (ClinicalTrials.gov identifier: NCT01462890 ), patients with newly diagnosed International Federation of Gynecology and Obstetrics stage IIB-IV epithelial ovarian, fallopian tube, or peritoneal cancer underwent primary cytoreductive surgery followed by six cycles of chemotherapy (paclitaxel 175 mg/m2 plus carboplatin area under the curve 5 once every 3 weeks) and bevacizumab (15 mg/kg once every 3 weeks). Patients were randomly assigned 1:1 to receive bevacizumab for either 15 or 30 months, stratified by International Federation of Gynecology and Obstetrics stage/residual tumor. The primary end point was investigator-assessed progression-free survival (PFS) according to RECIST version 1.1. Secondary end points included overall survival (OS), safety, and tolerability. RESULTS Between November 11, 2011, and August 6, 2013, 927 women were randomly assigned. There was no difference in PFS between treatment arms (hazard ratio, 0.99; 95% CI, 0.85 to 1.15; unstratified log-rank P = .90). Median PFS was 24.2 versus 26.0 months with standard versus extended duration of bevacizumab, respectively; restricted mean PFS was 39.5 versus 39.3 months, respectively. There was no OS difference between treatment arms (hazard ratio, 1.04; 95% CI, 0.87 to 1.23; P = .68). Serious/nonserious adverse events of special interest occurred in 29% versus 34% of patients in the standard versus experimental arms, respectively, and were consistent with the known safety profile of standard bevacizumab. CONCLUSION Longer treatment duration with bevacizumab for up to 30 months did not improve PFS or OS in patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer. A bevacizumab treatment duration of 15 months remains the standard of care.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · Journal Article
Dabreteau T, Maulard A, El Hajj H, Robert C, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026 · Journal Article
Papazyan T, Martin E, Pautier P, Guerin-Charbonnel C, et al.
Critical reviews in oncology/hematology · 2025 · Journal Article
Penel N, Pautier P, Blay JY
BMJ open · 2025 · Journal Article
Alexandre J, Boudier P, Lavit E, Asselain B, et al.
Cancers · 2024 · Journal Article
Zoghbi M, Patel BA, Roulleaux Dugage M, Mezquita L, et al.
The New England journal of medicine · 2024 · Letter
Pautier P, Blay JY, Duffaud F
The New England journal of medicine · 2024 · Journal Article
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, et al.
Bulletin du cancer · 2024 · English Abstract
Ouali K, Michels J, Blanc-Durand F, Leary A, et al.
The Lancet. Oncology · 2024 · Journal Article
Pautier P
International journal of radiation oncology, biology, physics · 2024 · Journal Article
Laville A, Ka K, El-Ayachi R, Achkar S, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023 · Journal Article
Joneborg U, Bergamini A, Wallin E, Mangili G, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · Journal Article
Harter P, Marmé F, Redondo A, Reuss A, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · Clinical Trial, Phase III
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, et al.
Gynecologic oncology · 2024 · Journal Article
Moore KN, Lorusso D, Oaknin A, Oza A, et al.
Gynecologic oncology · 2024 · Journal Article
Berton D, Pautier P, Lorusso D, Gennigens C, et al.
Gynecologic oncology · 2025 · Journal Article
Chator C, Chevrier M, Frenel JS, Guyon F, et al.
The oncologist · 2025 · Journal Article
Rippstein N, Zemmour C, Rodrigues M, Ray-Coquard I, et al.
Biomarker research · 2023 · Letter
Kfoury M, Hazzaz RE, Sanson C, Durand FB, et al.
BMC medicine · 2025 · Journal Article
Dubot C, Ray-Coquard I, Lequesne J, Pautier P, et al.
Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers
Abstract Background In addition to anti-PD(L)1, anti-CTLA-4 and anti-LAG-3, novel immune checkpoint proteins (ICP)-targeted antibodies have recently failed to demonstrate significant efficacy in clinical trials. In these
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients
Abstract Genomic testing is crucial for the management of ovarian cancer. DNA from biopsies at diagnostic laparoscopies or interval debulking surgery after neoadjuvant chemotherapy, has a high failure rate. At relapse, b
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients
Abstract Genomic testing is crucial for the management of ovarian cancer. DNA from biopsies at diagnostic laparoscopies or interval debulking surgery after neoadjuvant chemotherapy, has a high failure rate. At relapse, b
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · Randomized Controlled Trial
Pfisterer J, Joly F, Kristensen G, Rau J, et al.